- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00445250
The Role of Calcipotriol as Radioprotector of Skin
Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast.
Examining the hypothesis that protecting keratinocytes by calcipotriol can prevent in-vivo cutaneous side effect in patients receiving radiotherapy to the breast.
To check the connection between the skin effect of radiotherapy and different parameters including diseases such as diabetes and lupus, use of medications, allergies, weight, habits, size of the irradiated breast, previous chemotherapy treatment and exposure to sunlight.
Study Overview
Detailed Description
STUDY PROTOCOL
Fifty women diagnosed with breast cancer planned to receive adjuvant radiotherapy, will participate in the study. About 15 minutes after receiving the daily radiation dose fraction, a cream containing an active vitamin D analogue will be applied to half of the breast with inspection of a nurse. The other half of the breast will have a standard cream applied . During the days that radiotherapy is not administered the standard cream will be applied to both halves of the breast in a case of strong reaction to radiotherapy (e.g. strong erythema, painful tenderness etc.)The adverse skin effects will be assessed according to the following criteria:
. an assessment by a physician and a nurse according to the RTOG score (6).
As follows:
Grade 0 - no reaction. Grade 1 - light erythema dry peeling, decrease in sweat production. Grade 3 - extensive moist peeling, pitting edema. Grade 4 - ulcers, bleeding and necrosis.
- . A questionnaire to each patient regarding the efficacy and safety of the cream.
- . Number of interruption of radiotherapy treatment. The assessment will be done each week during radiotherapy treatment and weekly for three weeks following the completion of radiotherapy treatment.
Safety report will be sent to the local independent ethics committee after the examination of the first ten patients.
The protective effect of the cream containing calcipotriol will be compared to the standard treatment and analyzed statistically using the parameters mention above. The relation between the background disease, medications, allergies, weight, habits, size of the irradiated breast, sun exposure, previous chemotherapy treatment and exposure to sunlight and the skin reaction will be evaluated.
INCLUSION CRITERIA
- . Age ranging from 18 to 75.
- . Confirmed histological diagnosis of Breast cancer.
- . Radiotherapy treatment to the breast following lumpectomy.
EXCLUSION CRITERIA
- . Scleroderma.
- . An extremely large breast. Interfiled above 25 cm.
- . Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication.
- . Mastectomy.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Eyal Fenig, M.D.
- Phone Number: 97239377964
- Email: efenig@clalit.org.il
Study Contact Backup
- Name: Ofer Purim, M.D.
- Phone Number: 97239377973
- Email: oferp@clalit.org.il
Study Locations
-
-
-
Petach Tiqva, Israel, 49100
- Rabin Medical Center
-
Contact:
- Eyal Fenig, M.D.
- Phone Number: 97239377964
- Email: efenig@clalit.org.il
-
Contact:
- Ofer Purim, M.D.
- Phone Number: 97239377973
- Email: oferp@clalit.org.il
-
Principal Investigator:
- Eyal Fenig, M.D.
-
Sub-Investigator:
- Ofer Purim, M.D.
-
Sub-Investigator:
- Amir Abramovich, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ranging from 18 to 75.
- Confirmed histological diagnosis of Breast cancer.
- Radiotherapy treatment to the breast following lumpectomy.
Exclusion Criteria:
- Scleroderma.
- An extremely large breast. Interfiled above 25 cm.
- Prior radiotherapy to the same breast, radiotherapy to the contra lateral breast is not a contraindication.
- Mastectomy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Prevention of radiodermatitis
|
Secondary Outcome Measures
Outcome Measure |
---|
Side effects of Calcipotriol
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eyal Fenig, M.D., Rabin Medical Center
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 004253
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiodermatitis
-
Cairo UniversityRecruitingRadiodermatitis; AcuteEgypt
-
Jessa HospitalHasselt UniversityCompletedRadiation Dermatitis | Radiodermatitis; AcuteBelgium
-
University of Nove de JulhoWithdrawnPalliative Care | Cancer Patients | Radiotherapy Side Effect | Radiodermatitis; AcuteBrazil
-
University of Nove de JulhoCompletedHead and Neck Cancer | Radiotherapy Side Effect | Radiodermatitis; AcuteBrazil
-
ProTechSure Scientific, Inc.Poudre Valley Health SystemTerminated
-
Antonio J. Conde MorenoUniversity of ValenciaRecruiting
-
Second Affiliated Hospital of Soochow UniversityUnknown
-
University of BrasiliaUniversity of Washington; Conselho Nacional de Desenvolvimento Científico e...Unknown
-
Massachusetts General Hospital3MRecruiting
-
Instituto Nacional de Cancer, BrazilNot yet recruiting
Clinical Trials on Calcipotriol
-
LEO PharmaCompletedPsoriasis VulgarisBelgium, Canada, France, Germany, Netherlands, Spain, United Kingdom
-
DaniscoUniversity of Turku; 4Pharma Ltd.CompletedBorderline HypertensionFinland
-
LEO PharmaCompletedAtopic DermatitisUnited Kingdom, Finland, Canada, Denmark
-
Circassia LimitedBioskin GmbHCompletedPsoriasis VulgarisGermany
-
Wake Forest University Health SciencesWithdrawnCentral Centrifugal Cicatricial AlopeciaUnited States
-
Guangdong Provincial Hospital of Traditional Chinese...CompletedPsoriasis | Drug Effect | Drug Toxicity | Mesenchymal Stromal CellsChina
-
Xijing HospitalCompleted
-
LEO PharmaCompletedPsoriasis VulgarisFrance
-
EgymedicalpediaCompleted